About
Titles
Laboratory Assistant 3
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Tian-Min Chen's published research.
Publications Timeline
A big-picture view of Tian-Min Chen's research output by year.
Gary Désir, MD
Robert Safirstein, MD
Xiaojia (Sasha) Guo, PhD
Gilbert Moeckel, MD, PhD, FASN
Fred Sanford Gorelick, MD
David Rimm, MD, PhD
14Publications
127Citations
Publications
2023
APOBEC-1 deletion enhances cisplatin-induced acute kidney injury
Guo X, Blanc V, Davidson N, Velazquez H, Chen T, Moledina D, Moeckel G, Safirstein R, Desir G. APOBEC-1 deletion enhances cisplatin-induced acute kidney injury. Scientific Reports 2023, 13: 22255. PMID: 38097707, PMCID: PMC10721635, DOI: 10.1038/s41598-023-49575-3.Peer-Reviewed Original ResearchAltmetricmRNA Editing via the Apobec1 Gene Promotes Recovery from AKI
Guo X, Velazquez H, Xu L, Cheng Z, Chen T, Tian Y, Bewersdorf J, Blanc V, Davidson N, Safirstein R, Desir G. mRNA Editing via the Apobec1 Gene Promotes Recovery from AKI. Journal Of The American Society Of Nephrology 2023, 34: 451-451. DOI: 10.1681/asn.20233411s1451b.Peer-Reviewed Original ResearchRenalase Ameliorates AKI by Altering Mitochondrial Function to Induce Cellular Repair Mechanisms
Guo X, Chen R, Chen T, Safirstein R, Jonas E, Desir G. Renalase Ameliorates AKI by Altering Mitochondrial Function to Induce Cellular Repair Mechanisms. Journal Of The American Society Of Nephrology 2023, 34: 117-117. DOI: 10.1681/asn.20233411s1117b.Peer-Reviewed Original Research
2022
Apobec-1 Limits Cisplatin and Ischemia-Reperfusion-Induced AKI
Guo X, Xu L, Velazquez H, Chen T, Blanc V, Davidson N, Moeckel G, Safirstein R, Desir G. Apobec-1 Limits Cisplatin and Ischemia-Reperfusion-Induced AKI. Journal Of The American Society Of Nephrology 2022, 33: 359-360. DOI: 10.1681/asn.20223311s1359e.Peer-Reviewed Original ResearchRenalase Protects Renal Injury by Maintaining Mitochondrial Dynamic Homeostasis
Guo X, Chen R, Chen T, Moeckel G, Safirstein R, Jonas E, Desir G. Renalase Protects Renal Injury by Maintaining Mitochondrial Dynamic Homeostasis. Journal Of The American Society Of Nephrology 2022, 33: 359-359. DOI: 10.1681/asn.20223311s1359d.Peer-Reviewed Original ResearchInhibition of renalase drives tumour rejection by promoting T cell activation
Guo X, Jessel S, Qu R, Kluger Y, Chen TM, Hollander L, Safirstein R, Nelson B, Cha C, Bosenberg M, Jilaveanu LB, Rimm D, Rothlin CV, Kluger HM, Desir GV. Inhibition of renalase drives tumour rejection by promoting T cell activation. European Journal Of Cancer 2022, 165: 81-96. PMID: 35219026, PMCID: PMC8940682, DOI: 10.1016/j.ejca.2022.01.002.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPD-1 inhibitorsMurine melanoma modelMelanoma-bearing miceMelanoma modelTumor microenvironmentTumor rejectionCell death protein 1 (PD-1) inhibitorsAnti-PD-1 activityEnhanced T cell infiltrationT cell-dependent fashionMelanoma cellsMelanoma tumor regressionPreclinical melanoma modelsT cell infiltrationNatural killer cellsForkhead box P3Expression of IFNγWild-type miceProtein 1 inhibitorT cell activationTumor cell contentWild-type melanoma cellsCD4 cellsAdvanced melanomaAntibody treatment
2021
Heightened Innate Immune Response to COVID-19 Infection in CKD: Implications to Poorer Outcome During CKD
Guo X, Xu L, Chen T, Gorelick F, Desir G, Safirstein R. Heightened Innate Immune Response to COVID-19 Infection in CKD: Implications to Poorer Outcome During CKD. Journal Of The American Society Of Nephrology 2021, 32: 749-749. DOI: 10.1681/asn.20213210s1749c.Peer-Reviewed Original ResearchRenalase is a novel tissue and serological biomarker in pancreatic ductal adenocarcinoma
Gao Y, Wang M, Guo X, Hu J, Chen TM, Finn S, Lacy J, Kunstman JW, H. C, Bellin MD, Robert ME, Desir GV, Gorelick FS. Renalase is a novel tissue and serological biomarker in pancreatic ductal adenocarcinoma. PLOS ONE 2021, 16: e0250539. PMID: 34587190, PMCID: PMC8480607, DOI: 10.1371/journal.pone.0250539.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Pancreatic DuctalCase-Control StudiesFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedMonoamine OxidaseNeoplasm GradingPancreatic NeoplasmsPrognosisProspective StudiesRetrospective StudiesSurvival AnalysisUp-RegulationYoung AdultConceptsPlasma renalase levelsBorderline resectable PDACRenalase levelsPDAC precursor lesionsOverall survivalPDAC tissuesTumor characteristicsResectable PDACChronic pancreatitisPrecursor lesionsNormal pancreasPancreatic ductal adenocarcinoma growthAdvanced tumor characteristicsVaried clinical stagesWorse tumor characteristicsNode-positive diseasePancreatic ductal adenocarcinomaNormal pancreatic headSpindle-shaped cellsPlasma renalaseRenalase expressionUnderwent resectionAbdominal traumaPancreatic headPositive disease
2020
Kidney Targeted Renalase Agonist Peptide Rescues Severe Model of Cisplatin-Induced AKI and CKD
Guo X, Xu L, Velazquez H, Chen T, Williams R, Heller D, Safirstein R, Desir G. Kidney Targeted Renalase Agonist Peptide Rescues Severe Model of Cisplatin-Induced AKI and CKD. Journal Of The American Society Of Nephrology 2020, 31: 230-230. DOI: 10.1681/asn.20203110s1230b.Peer-Reviewed Original ResearchApobec 1 Limits Cisplatin-Induced AKI by Regulating the Disposal of Pro-Ferroptotic Lipids
Guo X, Velazquez H, Chen T, Blanc V, Davidson N, Safirstein R, Desir G. Apobec 1 Limits Cisplatin-Induced AKI by Regulating the Disposal of Pro-Ferroptotic Lipids. Journal Of The American Society Of Nephrology 2020, 31: 123-123. DOI: 10.1681/asn.20203110s1123d.Peer-Reviewed Original Research